The company expects to recruit around 120 patients at approximately 20 centers in the US and Canada.
The study is designed to demonstrate a reduction in plaque inflammation following treatment as quantified by FDG-PET imaging (18F 2-deoxyglucose positron emission tomography).
BioInvent said the antibody has been developed in collaboration with Genentech, a member of the Roche Group.
BioInvent CEO Svein Mathisen said the results from this phase II clinical trial will provide further insights into BI-204’s ability to reduce plaque inflammation and how it potentially can add to current treatment of coronary heart disease.